bruno.jpg Bruno Angelici Non-Executive Chairman
  • R
  • N
Appointment to the board

Bruno Angelici was appointed to the Vectura Board on 1 December 2013 and became Non‑Executive Chairman in February 2014. Following the merger with Skyepharma in June 2016, Bruno became Chairman of the enlarged Vectura Group plc.

Experience and expertise

Bruno has an MBA (Kellogg School of Management) and business and law degrees from Reims. Bruno’s career includes senior management roles in pharmaceutical and medical device companies. Bruno retired from AstraZeneca in 2010 as Executive Vice President International after a 20-year career. He was responsible for Europe, Japan, Asia Pacific, Latin America, the Middle East and Africa having originally joined as president of ICI Pharmaceuticals France. Prior to this, he was at Baxter, a US-based global supplier of medical devices. He has extensive international experience, including in the US, and brings a deep understanding to the Company of the medical device and pharmaceutical industries.

External appointments

Bruno is a non-executive director of Smiths Group plc, a technology group. In March 2017, Bruno stepped down as a non-executive director of Novo Nordisk A/S, a global healthcare company and world leader in diabetes care. He is a member of the Global Advisory Board of Takeda Pharmaceutical Company Ltd, Japan, the largest pharmaceutical company in Asia, and a member of the supervisory board of Wolters Kluwer NV, a global information services and publishing company.

james.jpg James Ward-Lilley Chief Executive Officer
Appointment to the board

James Ward-Lilley was appointed Chief Executive Officer of Vectura in September 2015 and became CEO of the enlarged Group following the merger with Skyepharma in June 2016.

Experience and expertise

James holds an Institute of Marketing Diploma, a BA (Hons) degree and an MBA. Prior to joining Vectura, James was a senior executive at AstraZeneca, being vice president respiratory, inflammation & autoimmunity, global product and portfolio strategy (GPPS). In this role James had responsibility for the development of AstraZeneca’s respiratory, inflammation and autoimmunity (RIA) strategy which included the acquisitions of Almirall’s respiratory business and Pearl Therapeutics. Prior to this, James led the AstraZeneca investor relations team from 2011 to 2012. His extensive international management career at AstraZeneca spanned 28 years across a variety of commercially focused roles. James progressed from sales and marketing roles in the UK through to country head of Belgium and Luxembourg. He then led AstraZeneca’s business in China to become the number one pharmaceutical company in that market. James went on to become regional vice president for Central Eastern Europe and the Middle East, where the business enjoyed strong growth.

andrew.jpg Andrew Derodra Chief Financial Officer
Appointment to the board

Andrew Derodra was appointed Chief Financial Officer (CFO) on 10 June 2016 having previously been appointed CFO of Skyepharma in November 2013

Experience and expertise

He is a Fellow of the Chartered Institute of Management Accountants and holds a BA (Hons) in mathematics from Oxford University. Andrew brings to the role over 25 years’ experience in senior finance and commercial roles in multinational FTSE 100 companies. Prior to Skyepharma he was with Tate & Lyle where he was Group Vice President Finance & Control from 2011. Previously, at SABMiller, he held a succession of commercial and strategic roles culminating in business transformation director – Europe. He held senior finance roles in several industries and sectors with Diageo, British Airways and Reed Elsevier.

frank.jpg Frank Condella Non-Executive Vice Chairman
  • N
  • A
Appointment to the board

Frank Condella was appointed as non-executive chairman of Skyepharma on 1 January 2010, having originally joined that company’s board as chief executive officer in March 2006. Following the merger with Vectura, he was appointed to the Board on 10 June 2016 as Non-Executive Vice Chairman.

Experience and expertise

He holds a BS in pharmacy and an MBA from Northeastern University, US. Frank brings over 30 years’ experience in the pharmaceutical industry to the Board. He is a non-executive director of Juniper Pharmaceuticals Inc. and Palladio Biosciences Inc. Previously, he was president and CEO of Juniper Pharmaceuticals, has served as a non-executive director of Fulcrum Pharma Ltd and Prosonix Ltd and was president of European Operations at IVAX, Chief executive officer of Faulding Pharmaceuticals, vice president of the Specialty Care Products business at Roche and vice president and general manager of the Lederle unit of American Home Products (Pfizer).

External appointments

Frank is a non-executive director of Juniper Pharmaceuticals Inc,. and Palladio Biosciences Inc,.

susan.jpg Susan Foden Non-Executive Director and Senior Independent Director
  • R
  • N
Appointment to the board

Dr Susan Foden joined the Vectura Board in January 2007.

Experience and expertise

She holds an MA and a DPhil in biochemistry from Oxford University. Susan brings significant experience in venture capital, UK biotech and healthcare companies to the Board. Prior to undertaking a plural career, from 2000 to 2003 she was an investor director with the London-based venture capital firm Merlin Biosciences Limited, and was chief executive officer of the technology transfer company Cancer Research Campaign Technology Ltd from 1987 to 2000.

External appointments

Susan holds a number of non-executive directorships with both public and private companies in the biotech and healthcare field, including
BTG plc, BerGenBio ASA, the Cell and Gene Therapy Catapult and Evgen Pharma plc.

per.jpg Per-Olof Andersson Non-Executive Director
  • N
  • A
Appointment to the board

Dr Per-Olof Andersson joined the Vectura Board in April 2015.

Experience and expertise

He holds a degree in medicine from Lund University, Sweden. Per-Olof is an expert in international research and development within the pharmaceuticals, bio-pharmaceuticals and speciality pharmaceutical industry and has considerable experience in respiratory therapeutic development. In 2011, Per-Olof retired from Almirall where he was executive director for R&D and a member of the board of directors. Prior to joining Almirall in 2006, Per-Olof had a distinguished international career at Pharmacia and Pfizer over a period of nearly 20 years. Since 2011, Per-Olof has been an independent consultant advising biotech and pharma companies.

neil.jpg Neil Warner Non-Executive Director
  • R
  • A
Appointment to the board

Neil Warner was appointed to the Board of Vectura as a Non-Executive Director in February 2011.

Experience and expertise

Neil holds an economics degree from the University of Leeds and is a Fellow of the Institute of Chartered Accountants.
Neil brings significant financial and leadership experience in multinational listed companies. He was finance director at Chloride Group plc, a position he held for 14 years until the company’s acquisition by Emerson Electric. Prior to this, Neil spent six years at Exel plc (formerly Ocean Group plc and acquired by DHL/Deutsche Post in December 2005), where he held a number of senior posts in financial planning, treasury and control. He has also held senior positions in Balfour Beatty plc (formerly BICC Group plc), Alcoa and PricewaterhouseCoopers and was a non-executive director of Dechra Pharmaceuticals plc, where he was the senior independent director and chair of the audit committee.

External appointments

Neil is senior independent director and audit committee chair of Trifast plc, a global leader in design, technology and manufacturing of industrial fasteners for the automotive and technology sectors. He is also a non-executive director, chair of the audit committee and member of the remuneration committee of Directa Plus plc which floated on AIM in May 2016. Directa Plus is one of the world’s largest producers of graphene-based materials – marketed under its “Graphene Plus” (G+) brand, which can be used by third parties in a wide variety of industrial and commercial applications. Neil was formerly the non-executive chairman of Enteq Upstream plc, a specialist reach and recovery products and technologies provider to the upstream oil and gas services market.

thomas.jpg Dr Thomas Werner Non-Executive Director
  • R
  • A
Appointment to the board

Thomas Werner was appointed to the Board of Skyepharma as a Non-Executive Director in May 2009 and joined the Board of Vectura following the merger in June 2016.

Experience and expertise

Dr Thomas Werner holds a degree in chemistry from the University of Göttingen. Thomas Werner has over 30 years of experience in the pharmaceutical industry, previously as senior vice president of GlaxoSmithKline where he was managing director for Germany and also co-ordinated its European oncology business. Prior to that, he was responsible for Glaxo Wellcome Germany and Central Europe, Bristol-Myers Squibb Germany and Convatec Germany/Central Europe. He has held various non-executive positions including Riemser Pharma GmbH and New Oncology AG. Beside his business responsibilities he has previously served for many years on the board of trustees of the Paul Ehrlich Foundation and the Robert Koch Foundation and was a director of the American Chamber of Commerce in Germany representing healthcare companies.

External appointments

Thomas is chairman of Fertin Pharma, a Danish medicated chewing gum company, and sits on the boards of Basilea Pharmaceutica Ltd and BSN Medical. He is chairman of the investor advisory committee Thomas Werner of the Seventure (France) Health for Life capital investment fund.

Committee membership

  • RRemuneration Committee
  • NNomination Committee
  • AAudit Committee
  • Committee chairman
james.jpg James Ward-Lilley Chief Executive Officer
Appointment

James Ward-Lilley was appointed Chief Executive Officer of Vectura in September 2015 and became CEO of the enlarged Group following the merger with Skyepharma in June 2016.

Experience and expertise

James holds an Institute of Marketing Diploma, a BA (Hons) degree and an MBA. Prior to joining Vectura, James was a senior executive at AstraZeneca, being vice president respiratory, inflammation & autoimmunity, global product and portfolio strategy (GPPS). In this role James had responsibility for the development of AstraZeneca’s respiratory, inflammation and autoimmunity (RIA) strategy which included the acquisitions of Almirall’s respiratory business and Pearl Therapeutics. Prior to this, James led the AstraZeneca investor relations team from 2011 to 2012. His extensive international management career at AstraZeneca spanned 28 years across a variety of commercially focused roles. James progressed from sales and marketing roles in the UK through to country head of Belgium and Luxembourg. He then led AstraZeneca’s business in China to become the number one pharmaceutical company in that market. James went on to become regional vice president for Central Eastern Europe and the Middle East, where the business enjoyed strong growth.

andrew.jpg Andrew Derodra Chief Financial Officer
Appointment to the board

Andrew Derodra was appointed Chief Financial Officer (CFO) on 10 June 2016 having previously been appointed CFO of Skyepharma in November 2013.

Experience and expertise

Andrew is a Fellow of the Chartered Institute of Management Accountants and holds a BA (Hons) in mathematics from Oxford University. Andrew brings to the role over 25 years’ experience in senior finance and commercial roles in multinational FTSE 100 companies. Prior to Skyepharma he was with Tate & Lyle where he was Group Vice President Finance & Control from 2011. Previously, at SABMiller, he held a succession of commercial and strategic roles culminating in business transformation director – Europe. He held senior finance roles in several industries and sectors with Diageo, British Airways and Reed Elsevier.

john.jpg John Murphy General Counsel and Company Secretary
Appointment

John Murphy joined Skyepharma as General Counsel in March 2006 and was appointed as General Counsel and Company Secretary of Vectura in June 2016 following the merger.

Experience and expertise

John is a lawyer with extensive experience in legal and company secretarial roles in listed pharmaceutical and biotechnology companies including Medeva PLC, Celltech Group PLC and Pharmagene PLC. He is chairman of the BIA Intellectual Property Advisory Committee and a member of the EuropaBio Intellectual Property Working Group. He holds a BSc in aeronautical engineering from Bristol University and is a qualified solicitor.

geraldine.jpg Geraldine Venthoye Executive Vice President - Pharmaceutical Development
Appointment

Dr Geraldine Venthoye joined Vectura in June 2016 upon completion of the merger with Skyepharma PLC, where she had been Executive Vice President Pharmaceutical Development since 2013, having joined Skyepharma as Head of Inhalation Business Unit in September 2003.

Experience and expertise

Geraldine is a UK registered pharmacist and holds a doctorate degree in Pharmaceutics from the University of London. Geraldine held senior CMC leadership and scientific roles in Inhale/ Nektar Therapeutics, San Carlos, California, US, and prior to this in the UK, held scientific positions in inhalation drug delivery at Vandsons Research and Norton Healthcare.

roger.jpg Roger Heerman Executive Vice President - Commercial and Business Development
Appointment

Roger Heerman joined Vectura in 2010 and was appointed to the Executive Leadership Team in 2013.

Experience and expertise

Prior to joining Vectura, Roger gained extensive US and international commercialisation experience in a number of senior roles, including vice president sales and marketing of the US publicly held company Critical Therapeutics, Inc. and as vice president, director of client service at McK Healthcare. At Critical Therapeutics, he was responsible for the build-out of the commercial infrastructure and the launch of ZYFLO CR in the US. At McK Healthcare, Roger supported the launch and repositioning efforts of numerous US and global brands, including UCB’s Neupro® for Parkinson’s disease and IROKO’s Aggrastat® for acute coronary syndrome. Roger began his career in the pharmaceutical industry as a sales representative in the respiratory division at GlaxoSmithKline. He received his BS from Babson College and his MBA from the F.W. Olin School of Business at Babson College.

gonzalo.jpg Gonzalo de Miquel Chief Medical Officer & Executive Vice President Development
Appointment

Gonzalo de Miquel joined Vectura on 15 February 2017.

Experience and expertise

Gonzalo has highly relevant medical and product development experience ranging from pharmacovigilance and regulatory through to early and late stage clinical development and medical affairs. Prior to joining Vectura, Gonzalo was Vice President of Clinical Development at Astra Zeneca with responsibility for the overall strategy, organisation, resource assignment and project prioritisation across Astra Zeneca’s portfolio.
Gonzalo trained in Internal medicine and Rheumatology practising for six years in Barcelona before moving into the pharmaceutical industry. Gonzalo has held senior positions including global clinical lead for respiratory autoimmunity at Boehringer working in early clinical development as well as the late-stage and launch of Spiriva in Spain and with Almirall as Director of Global Clinical Development, successfully leading their aclidinium franchise development through to FDA and EMA approvals in 2012 and previously as their head of Global Medical Affairs.

 

david.jpg David Lescuyer Executive Vice President - Oral Business
Appointment

David joined Vectura in June 2016 upon completion of the merger with Skyepharma PLC where he had been Executive Vice President, Oral Business, since April 2016.

Experience and expertise

David, a French national, holds a B.Sc. in Mechanical Engineering and MBA from HEC Paris. David joined Skyepharma from Patheon Pharmaceuticals where he was Executive Director and General Manager, Patheon France and more recently Global VP, Operational Excellence. Prior to Patheon, David's career included experience with Fareva, Cenexi and Catalent in senior operational and general management roles.

jo.jpg Joanne Hombal Human Resources Director
Appointment

Joanne Hombal joined Vectura in January 2015.

Experience and expertise

Joanne has a BSc in psychology from the University of Birmingham, a postgraduate diploma in human resource management from the University of Glamorgan and is a Chartered Member of the Institute of Personnel and Development. Before joining Vectura, Joanne was vice president HR at Invensys Rail, with responsibility for setting and leading the people strategy for Northern Europe. She has also held senior HR roles in the financial services and ICT industries and led a number of organisational development and transformation initiatives.

back to top